Phospho-IRAK1 (T209) Antibody

What is the biological significance of IRAK1 phosphorylation at T209?

The phosphorylation of IRAK1 at threonine 209 represents a vital step in the activation process of this kinase. IRAK1 is a serine/threonine-protein kinase that functions as a critical mediator in innate immune response pathways. The T209 residue specifically is essential for IRAK1 kinase activity, making it a key regulatory point in the signal transduction cascade . Phosphorylation at this site occurs during the multistep process following Toll-like receptor (TLR) or IL-1 receptor (IL-1R) stimulation. When these receptors are activated, IRAK1 interacts with MyD88, which is rapidly recruited to the receptor complex. This interaction leads to IRAK1 phosphorylation by IRAK4, followed by autophosphorylation that fully activates IRAK1 .

The phosphorylated IRAK1 subsequently detaches from the receptor complex and binds to E3 ubiquitin ligase and TRAF6, ultimately activating the NF-κB signaling pathway. This activation cascade is fundamental to inflammatory responses and innate immunity against pathogens . Researchers investigating inflammatory processes should prioritize understanding this phosphorylation event as it represents a critical control point in immune signaling.

How does IRAK1 T209 phosphorylation differ from other phosphorylation sites on the protein?

IRAK1 undergoes phosphorylation at multiple sites, but the T209 residue holds particular importance for kinase functionality. Unlike other phosphorylation sites such as S376 (which appears minimally expressed in certain liver cancer cell lines), the T209 phosphorylation has been demonstrated to be the predominant active form in multiple experimental models .

Studies using hepatocellular carcinoma (HCC) cell lines have shown that while p-IRAK1 (T209) was significantly expressed and functionally relevant, p-IRAK1 (S376) was almost undetectable in SMMU-7721 and HepG2 cells . This differential phosphorylation pattern suggests that T209 phosphorylation may serve as the primary regulatory mechanism for IRAK1 activity in certain cellular contexts. When designing experiments targeting IRAK1 signaling, researchers should consider these site-specific differences to accurately interpret results and develop targeted interventions.

What criteria should be applied when selecting a Phospho-IRAK1 (T209) antibody for specific research applications?

Selection of an appropriate Phospho-IRAK1 (T209) antibody requires careful consideration of several technical parameters based on your experimental design:

When selecting between available antibodies, examine the validation data provided by manufacturers. For instance, the antibody described in source has been specifically validated to detect endogenous levels of IRAK1 protein only when phosphorylated at T209, making it suitable for studies where distinguishing between phosphorylated and non-phosphorylated forms is critical . Additionally, consider the purification method, as antibodies purified by affinity chromatography may offer higher specificity than those that undergo less rigorous purification processes .

How can researchers validate the specificity of Phospho-IRAK1 (T209) antibody in their experimental system?

Validation of phospho-specific antibodies requires multiple complementary approaches to ensure reliable results:

• Phosphatase Treatment Control: Treat half of your sample with lambda phosphatase before immunoblotting. The signal should disappear in the phosphatase-treated sample if the antibody is truly phospho-specific.

• IRAK1/4 Inhibitor Treatment: Utilize IRAK1/4 inhibitors as negative controls. As demonstrated in HCC research, treatment with these inhibitors significantly reduces phosphorylation at T209, providing a functional validation approach . Studies have shown dose-dependent inhibition of p-IRAK1 (T209) with corresponding functional effects, confirming both antibody specificity and biological relevance.

• Knockout/Knockdown Verification: Employ IRAK1 knockdown via siRNA alongside your phospho-specific antibody detection. Both total IRAK1 and phospho-IRAK1 signals should diminish, confirming specificity.

• Stimulation Experiments: Stimulate cells with IL-1 or TLR ligands, which should increase IRAK1 T209 phosphorylation. This functional validation approach connects antibody detection with known biological mechanisms.

• Cross-validation Using Multiple Techniques: If possible, verify your findings using alternative detection methods such as mass spectrometry to confirm phosphorylation at the T209 residue.

These rigorous validation steps ensure that experimental outcomes reflect genuine biological phenomena rather than technical artifacts.

What are the optimal experimental conditions for detecting IRAK1 T209 phosphorylation in different cellular models?

Detection of IRAK1 T209 phosphorylation requires careful optimization of experimental conditions tailored to your cellular model:

• Stimulation Timing: IRAK1 phosphorylation occurs rapidly after receptor stimulation, typically peaking within 5-30 minutes of IL-1 or TLR ligand treatment. Time-course experiments are essential to capture the phosphorylation peak in your specific cell type.

• Lysis Buffer Composition: Use phosphatase inhibitor-rich lysis buffers to preserve phosphorylation status. Include sodium fluoride (50mM), sodium orthovanadate (1mM), and β-glycerophosphate (10mM) in standard RIPA buffer.

• Sample Handling: Process samples quickly at 4°C to minimize dephosphorylation. Flash-freezing samples in liquid nitrogen immediately after collection helps preserve phosphorylation status.

• Application-Specific Dilutions:

  • For Western blotting: Starting dilution of 1/500 - 1/2000

  • For ELISA: Higher dilutions of approximately 1/40000

  • For IHC-P: Optimization required based on tissue fixation methods

• Cell Type Considerations: Different cell types express varying levels of IRAK1 and exhibit different phosphorylation kinetics. For instance, liver cancer cell lines like SMMU-7721 and HepG2 show robust p-IRAK1 (T209) expression compared to the minimal expression of p-IRAK1 (S376) .

For researchers working with challenging samples, signal amplification systems may be necessary when endogenous phosphorylation levels are low.

How should researchers interpret discrepancies in IRAK1 T209 phosphorylation data across different experimental platforms?

When faced with discrepancies in phosphorylation data, consider these methodological factors:

• Antibody Clone Variation: Different antibody clones may recognize slightly different epitopes around the phosphorylation site. For example, the synthetic peptide immunogens used to generate these antibodies range from approximately aa 150-250 around the T209 site , which could affect epitope recognition patterns.

• Sample Preparation Impact: Phosphorylation status can be significantly affected by preparation methods:

  • Formalin fixation (for IHC) may mask epitopes, requiring optimization of antigen retrieval

  • Denaturing conditions in SDS-PAGE may affect epitope conformation

  • Native conditions in ELISA may preserve certain conformational epitopes

• Biological Context Variation: The phosphorylation of T209 varies significantly between biological contexts. For instance, research has demonstrated that IRAK1 phosphorylation at T209 is substantially higher in hepatocellular carcinoma tissues compared to adjacent non-tumor tissues , suggesting context-dependent regulation.

• Cross-platform Validation Strategy: When discrepancies arise, employ a systematic cross-validation approach:

  • Verify findings using multiple antibody clones

  • Compare results across different detection methods (WB, ELISA, IHC)

  • Correlate phosphorylation with functional outcomes using inhibitor studies

  • Consider mass spectrometry as a definitive method for phosphorylation site verification

By implementing this structured troubleshooting approach, researchers can determine whether discrepancies reflect technical limitations or genuine biological variability.

What methodological approaches can researchers use to study IRAK1 T209 phosphorylation in cancer models?

Investigating IRAK1 T209 phosphorylation in cancer models requires multi-dimensional experimental approaches:

• Cell Line Selection Strategy:

  • For hepatocellular carcinoma, SMMU-7721, HepG2, PVTT, and PLC/PRF/5 cell lines have demonstrated detectable p-IRAK1 (T209) levels

  • For hematological malignancies, models of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) show elevated IRAK1 expression and activation

• Functional Assessment Methods:

  • Proliferation assays: CCK-8 assays have demonstrated dose-dependent inhibition of cell growth following IRAK1/4 inhibitor treatment in HCC cell lines

  • Colony formation assays: Treatment with IRAK1 inhibitor (10μM and 20μM for 48h) significantly reduced colony formation in SMMU-7721 and HepG2 cells

  • Migration assays: IRAK1/4 inhibitor (20μM) decreases the number of migrated cells in SMMU-7721 cells

• In vivo Model Applications:

  • Xenograft models have confirmed the role of phosphorylated IRAK1 in promoting tumor growth, supporting in vitro findings

  • Patient-derived xenografts can provide more clinically relevant models for testing IRAK1 inhibition strategies

• Inhibitor-based Studies:

  • Dose-response relationships: Titration of IRAK1/4 inhibitor concentrations (typically 0-20μM) reveals phosphorylation-dependent effects on cancer cell phenotypes

  • Temporal dynamics: Time-course experiments track the kinetics of phosphorylation changes and corresponding phenotypic alterations

• Genetic Manipulation Approaches:

  • Site-directed mutagenesis of T209 to alanine (phospho-dead) or glutamic acid (phospho-mimetic) can dissect the specific contributions of this phosphorylation site

  • CRISPR/Cas9-mediated genome editing can create cellular models with modified IRAK1 phosphorylation sites

These methodological approaches provide complementary data sets that collectively illuminate the role of IRAK1 T209 phosphorylation in cancer biology.

How does IRAK1 T209 phosphorylation contribute to inflammatory disease mechanisms and potential therapeutic interventions?

IRAK1 T209 phosphorylation represents a pivotal regulatory point in inflammatory signaling and disease pathogenesis:

• Mechanistic Contributions to Inflammation:

  • Phosphorylated IRAK1 at T209 activates downstream NF-κB signaling, triggering pro-inflammatory cytokine production

  • The phosphorylation enables IRAK1 to phosphorylate interferon regulatory factor 7 (IRF7), inducing type I IFN gene transcription and antiviral responses

  • Phosphorylated IRAK1 can translocate to the nucleus when sumoylated, phosphorylating STAT3 and modulating additional inflammatory pathways

• Disease-Specific Phosphorylation Patterns:

  • Cancer progression: Elevated p-IRAK1 (T209) levels correlate with enhanced proliferation and migration in hepatocellular carcinoma

  • Hematological malignancies: Dysregulated IRAK1 signaling, including phosphorylation at T209, contributes to myelodysplastic syndrome and acute myeloid leukemia development

  • Other cancers: IRAK1 hyperactivation has been implicated in melanoma, lung cancer, and breast cancer

• Therapeutic Targeting Strategies:

  • Direct kinase inhibition: IRAK1/4 inhibitors prevent T209 phosphorylation and demonstrate anti-proliferative and anti-migratory effects in cancer models

  • Pathway modulation: Targeting upstream activators or downstream effectors of phosphorylated IRAK1 may provide alternative intervention points

  • Combination approaches: IRAK1 inhibitors may synergize with conventional therapies by simultaneously targeting multiple cancer-promoting pathways

• Potential Biomarker Applications:

  • Phosphorylated IRAK1 (T209) levels may serve as predictive biomarkers for response to IRAK1-targeted therapies

  • Changes in phosphorylation status during treatment could function as pharmacodynamic markers of target engagement

The central role of IRAK1 T209 phosphorylation in inflammatory signaling makes it an attractive target for therapeutic intervention across multiple disease contexts, particularly in inflammation-driven malignancies .

What are the critical factors that affect phospho-IRAK1 (T209) antibody performance in different experimental systems?

Several technical factors significantly impact phospho-IRAK1 (T209) antibody performance:

• Buffer Composition Effects:

  • Storage buffers containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide help maintain antibody stability

  • Working buffers for various applications may require optimization:

    • For Western blotting: TBST with 3-5% non-fat dry milk or BSA as blocking agent

    • For ELISA: PBS-based buffers with precise pH control (7.2-7.4)

    • For IHC: Antigen retrieval conditions critically affect phospho-epitope detection

• Sample Preparation Considerations:

  • Fresh vs. frozen samples: Phosphorylation status is better preserved in flash-frozen samples

  • Tissue fixation impact: Formalin fixation can mask phospho-epitopes, requiring optimized antigen retrieval

  • Protein extraction methods: Harsh extraction conditions may alter phosphorylation status

• Cross-reactivity Management:

  • Potential cross-reactivity with other phosphorylated proteins must be evaluated, particularly in complex samples

  • Blocking with phosphopeptides corresponding to the immunogen sequence can confirm specificity

  • Pre-absorption controls with non-phosphorylated peptides can distinguish specific from non-specific binding

• Quantification Method Standardization:

  • Loading controls must be carefully selected, as traditional housekeeping proteins may vary across experimental conditions

  • Phosphorylation-specific loading controls can provide normalization specific to phosphorylation pathways

  • Multiple exposure times should be captured to ensure linearity of signal for accurate quantification

By addressing these technical considerations, researchers can enhance the reliability and reproducibility of their phospho-IRAK1 (T209) detection and quantification.

How can researchers effectively monitor dynamic changes in IRAK1 T209 phosphorylation during signaling events?

Capturing the dynamic nature of IRAK1 T209 phosphorylation requires specialized experimental approaches:

• Time-resolved Sampling Strategies:

  • Fine-grained time course: Collect samples at multiple timepoints (0, 5, 15, 30, 60, 120, 240 minutes) after stimulation

  • Pulse-chase designs: Stimulate briefly, then track phosphorylation decay after stimulus removal

  • Synchronized cell population approaches: Use cell cycle synchronization methods to reduce heterogeneity in signaling responses

• Live-cell Imaging Approaches:

  • Develop phospho-specific biosensors based on fluorescence resonance energy transfer (FRET)

  • Engineer cell lines expressing fluorescently tagged IRAK1 to track localization changes that correlate with phosphorylation status

  • Combine with optogenetic tools to precisely control pathway activation while monitoring phosphorylation

• Quantitative Mass Spectrometry Methods:

  • Stable isotope labeling with amino acids in cell culture (SILAC) enables precise quantification of phosphopeptides

  • Parallel reaction monitoring (PRM) provides targeted, sensitive detection of T209 phosphorylation

  • Phosphoproteomics analyses can place T209 phosphorylation in the broader context of pathway activation

• Kinase Activity Reporter Systems:

  • Custom peptide substrates containing the T209 sequence can monitor IRAK1 autokinase activity

  • In vitro kinase assays with recombinant IRAK1 can define the kinetics of T209 autophosphorylation

  • Cell-based reporter systems can translate phosphorylation events into readily measurable signals

These methodological approaches collectively enable researchers to move beyond static measurements and capture the dynamic regulation of IRAK1 T209 phosphorylation in various biological contexts.